Page last updated: 2024-11-04

vorinostat and Hepatitis B, Chronic

vorinostat has been researched along with Hepatitis B, Chronic in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Hepatitis B, Chronic: INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hsieh, YH1
Su, IJ1
Yen, CJ1
Tsai, TF1
Tsai, HW1
Tsai, HN1
Huang, YJ1
Chen, YY1
Ai, YL1
Kao, LY1
Hsieh, WC1
Wu, HC1
Huang, W1

Other Studies

1 other study available for vorinostat and Hepatitis B, Chronic

ArticleYear
Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients.
    Carcinogenesis, 2013, Volume: 34, Issue:2

    Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Nucleus; Cell Pro

2013